Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 15/20 | 1.00 |
| ▸ | PMM2 | O15305 | 12/20 | 1.00 |
| ▸ | PHOSPHO1 | Q8TCT1 | 12/20 | 1.00 |
| ▸ | G6PD | P11413 | 6/20 | 1.00 |
| ▸ | APOBEC3G | Q9HC16 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | CASP3 | P42574 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562926 | 1.00 | MPI (1.00) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL30738364 | 0.98 | MPI (0.96) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL29910151 | 0.85 | MPI (1.00) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL21033372 | 0.85 | MPI (0.74) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL2537846 | 0.85 | MPI (1.00) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL2443755 | 0.85 | MPI (1.00) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL1894451 | 0.85 | MPI (1.00) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL18913003 | 0.85 | MPI (0.74) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL1900552 | 0.85 | MPI (0.74) | MPIPMM2PHOSPHO1G6PDAPOBEC3G | |
| SCHEMBL8373516 | 0.85 | MPI (0.74) | MPIPMM2PHOSPHO1G6PDAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496231-B | Preparation method of N-phenyl-2, 3-dihydro-4H-1, 3-benzothiazine-4-ketone | 常州大学 | 2025-04-04 | — | — | CN | claimed |
| CN-116496231-A | Preparation method of N-phenyl-2, 3-dihydro-4H-1, 3-benzothiazine-4-ketone | 常州大学 | 2023-07-28 | — | — | CN | claimed |
| US-11707453-B2 | Treatment of unipolar depressive disorder | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-07-25 | — | — | US | claimed |
| EP-3448379-B1 | TREATMENT OF IMPULSIVITY-RELATED DISORDERS | UNIV OXFORD INNOVATION LTD (GB) | 2023-06-28 | — | — | EP | claimed |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | claimed |
| US-20210000803-A1 | TREATMENT OF UNIPOLAR DEPRESSIVE DISORDER | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-01-07 | — | — | US | claimed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | claimed |
| US-10653680-B2 | Treatment of impulsivity-related disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-05-19 | — | — | US | claimed |
| US-20190111029-A1 | TREATMENT OF IMPULSIVITY-RELATED DISORDERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | claimed |
| EP-2673048-A2 | TREATMENT OF BIPOLAR DISORDER | Isis Innovation Limited (GB) | 2013-12-18 | — | — | EP | claimed |
| WO-2012107735-A2 | TREATMENT OF BIPOLAR DISORDER | ISIS INNOVATION LTD (GB) | 2012-08-16 | — | — | WO | claimed |
| WO-2011062864-A2 | INHIBITORS OF NOX ENZYMES AND METHODS OF USE THEREOF | EMORY UNIVERSITY (US) | 2011-05-26 | — | — | WO | claimed |
| US-6001863-A | USEFUL AS ANTIVIRAL, ANTIINFLAMMATORY AND ANTIATHEROSCLEROSIS AGENT; ADMINISTERING TO THE PATIENT IN NEED OF ZINC EJECTION FROM NUCLEOCAPSID PROTEIN | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | claimed |
| EP-0644243-B1 | Anti-fouling compositions or fouling control of harmful aquatic oranisms | SUMITOMO CHEMICAL CO (JP) | 1999-01-27 | — | — | EP | claimed |
| US-5507862-A | PROTECTIVE COATINGS CONTAINING SUBSTITUTED N-PHENYLISOTHIAZOLONES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-04-16 | — | — | US | claimed |
| EP-0644243-A2 | Anti-fouling compositions or fouling control of harmful aquatic oranisms | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-03-22 | — | — | EP | claimed |
| JP-7233014-A | — | — | None | — | — | JP | disclosed |
| JP-8188506-A | — | — | None | — | — | JP | disclosed |
| EP-0644243-A2 | Anti-fouling compositions or fouling control of harmful aquatic oranisms | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0644243-A2 | Anti-fouling compositions or fouling control of harmful aquatic oranisms | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707453-B2 | Treatment of unipolar depressive disorder | SLC6A2, CHRM1, SLC1A2 | MPI 1405/4885PMM2 3009/4885PHOSPHO1 1285/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | MPI 321/4885PMM2 2645/4885PHOSPHO1 2868/4885 |
| US-20210000803-A1 | TREATMENT OF UNIPOLAR DEPRESSIVE DISORDER | SLC6A2, CHRM1, SLC1A2 | MPI 1405/4885PMM2 3009/4885PHOSPHO1 1285/4885 |
| US-20190111029-A1 | TREATMENT OF IMPULSIVITY-RELATED DISORDERS | DRD2, DRD3, DRD1 | MPI 2619/4885PMM2 3665/4885PHOSPHO1 3858/4885 |
| US-10653680-B2 | Treatment of impulsivity-related disorders | DRD2, DRD3, DRD1 | MPI 2619/4885PMM2 3665/4885PHOSPHO1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.